このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
ResMed 将来の成長
Future 基準チェック /26
ResMed利益と収益がそれぞれ年間13.5%と7.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に22.2% 12.8%なると予測されています。
主要情報
13.5%
収益成長率
12.8%
EPS成長率
Medical Equipment 収益成長 | 16.7% |
収益成長率 | 7.1% |
将来の株主資本利益率 | 22.1% |
アナリストカバレッジ | Good |
最終更新日 | 03 Jul 2024 |
今後の成長に関する最新情報
Recent updates
ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors
Apr 09A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Mar 26ResMed goes ex dividend tomorrow
Feb 07ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06ResMed: The GARP Story Continues, Technicals Showing Vital Signs
Jan 26Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention
Jan 23We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease
Dec 28Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)
Dec 16業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
6/30/2027 | 5,789 | 1,522 | 1,590 | 1,697 | 5 |
6/30/2026 | 5,387 | 1,374 | 1,411 | 1,518 | 19 |
6/30/2025 | 5,034 | 1,238 | 1,278 | 1,388 | 22 |
6/30/2024 | 4,677 | 1,023 | 1,155 | 1,261 | 22 |
3/31/2024 | 4,584 | 958 | 1,071 | 1,199 | N/A |
12/31/2023 | 4,504 | 890 | 944 | 1,079 | N/A |
9/30/2023 | 4,375 | 907 | 792 | 935 | N/A |
6/30/2023 | 4,223 | 898 | 559 | 693 | N/A |
3/31/2023 | 4,016 | 863 | 408 | 535 | N/A |
12/31/2022 | 3,763 | 809 | 222 | 370 | N/A |
9/30/2022 | 3,624 | 786 | 305 | 461 | N/A |
6/30/2022 | 3,578 | 779 | 195 | 351 | N/A |
3/31/2022 | 3,539 | 779 | 344 | 498 | N/A |
12/31/2021 | 3,444 | 522 | 446 | 577 | N/A |
9/30/2021 | 3,349 | 500 | 397 | 527 | N/A |
6/30/2021 | 3,197 | 475 | 620 | 737 | N/A |
3/31/2021 | 3,091 | 457 | 733 | 840 | N/A |
12/31/2020 | 3,092 | 699 | 774 | 884 | N/A |
9/30/2020 | 3,028 | 680 | 684 | 784 | N/A |
6/30/2020 | 2,957 | 622 | 696 | 802 | N/A |
3/31/2020 | 2,892 | 513 | 505 | 614 | N/A |
12/31/2019 | 2,784 | 455 | 420 | 514 | N/A |
9/30/2019 | 2,699 | 419 | 487 | 573 | N/A |
6/30/2019 | 2,607 | 405 | 382 | 459 | N/A |
3/31/2019 | 2,525 | 446 | 374 | 447 | N/A |
12/31/2018 | 2,455 | 450 | 385 | 456 | N/A |
9/30/2018 | 2,405 | 335 | 390 | 459 | N/A |
6/30/2018 | 2,340 | 316 | 434 | 505 | N/A |
3/31/2018 | 2,273 | 307 | 444 | 516 | N/A |
12/31/2017 | 2,196 | 285 | N/A | 434 | N/A |
9/30/2017 | 2,125 | 352 | N/A | 422 | N/A |
6/30/2017 | 2,067 | 342 | N/A | 414 | N/A |
3/31/2017 | 2,029 | 324 | N/A | 417 | N/A |
12/31/2016 | 1,968 | 327 | N/A | 474 | N/A |
9/30/2016 | 1,893 | 346 | N/A | 510 | N/A |
6/30/2016 | 1,839 | 352 | N/A | 548 | N/A |
3/31/2016 | 1,773 | 357 | N/A | 505 | N/A |
12/31/2015 | 1,742 | 357 | N/A | 471 | N/A |
9/30/2015 | 1,710 | 353 | N/A | 421 | N/A |
6/30/2015 | 1,679 | 353 | N/A | 383 | N/A |
3/31/2015 | 1,641 | 353 | N/A | 399 | N/A |
12/31/2014 | 1,616 | 352 | N/A | 409 | N/A |
9/30/2014 | 1,578 | 348 | N/A | 387 | N/A |
6/30/2014 | 1,555 | 345 | N/A | 391 | N/A |
3/31/2014 | 1,554 | 331 | N/A | 400 | N/A |
12/31/2013 | 1,540 | 325 | N/A | 406 | N/A |
9/30/2013 | 1,532 | 317 | N/A | 415 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: RMDの予測収益成長率 (年間13.5% ) は 貯蓄率 ( 2.4% ) を上回っています。
収益対市場: RMDの収益 ( 13.5% ) US市場 ( 14.8% ) よりも低い成長が予測されています。
高成長収益: RMDの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: RMDの収益 ( 7.1% ) US市場 ( 8.7% ) よりも低い成長が予測されています。
高い収益成長: RMDの収益 ( 7.1% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: RMDの 自己資本利益率 は、3年後には高くなると予測されています ( 22.2 %)